Five-flavor Sophora flavescens enteric-coated capsules for ulcerative colitis: ethnopharmacological rationale, pharmacology, clinical evidence, and safety
- 1The First Clinical Medical College, Bengbu Medical University
- 2Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Abstract
Five-flavor Sophora flavescens enteric-coated capsules (FSEC), also reported as Wuwei Kushen or composite Sophora colon-soluble capsules, are used in China for ulcerative colitis (UC) associated with intestinal damp-heat, bloody diarrhea, and mucosal injury. This critical narrative Review evaluates the traditional rationale, product identity, material basis, pharmacological evidence, clinical findings, and safety of FSEC. PubMed, Web of Science, ScienceDirect, CNKI, Wanfang, and reference lists were searched through May 2026 and selectively updated through 18 August 2026. The Four Pillars of Best Practice in Ethnopharmacology and the ConPhyMP guidelines informed appraisal of identity, characterization, dose, and evidence attribution. The defined five-material product contains S. flavescens , Sanguisorba officinalis , Indigo naturalis, Bletilla striata , and Glycyrrhiza uralensis . Complete-formulation experiments support effects on microbial short-chain-fatty-acid signaling, GPR43, NLRP3/STAT3, AGE-RAGE/NF-κB, epithelial barrier integrity, and ferroptosis-related changes. Constituent studies broaden biological plausibility but cannot establish the efficacy or safety of the complete product. Older randomized trials and meta-analyses suggest short-term benefit, whereas recent single-center cohorts provide provisional adjunctive evidence because of nonrandomized designs and incomplete batch reporting. FSEC is therefore a plausible colon-targeted ethnopharmacological intervention, but confirmatory studies require chemically defined batches, verified release and exposure, internationally accepted UC endpoints, prospective multicenter designs, and active monitoring for hepatic, cardiopulmonary, electrolyte, and interaction risks.
Related
- Optimization of core-shell capsules properties (Olive oil/alginate) obtained by dripping coextrusion process
- Hidden Medicines in Herbarium Collections: Medicinal Plant Diversity and Ethnopharmacological Knowledge from GSUH, Nigeria
- Pharmacognostic Profile and Ethnopharmacological Significance of Selected Medicinal Plants Distributed on Mount Khvamli
- Drug-Development Potential of Muntingia calabura L.: A Systematic Review of Ethnopharmacological Use, Pharmacological Potency, Preclinical Evidence, and Plant-Mediated Nanotechnology
- Ethnopharmacological study of medicinal plants used for breast cancer treatment among traditional herbalists and patients in Central and Western Cameroon.
BibTeX
@article{ma2026fiveflavor,
title = {{Five-flavor Sophora flavescens enteric-coated capsules for ulcerative colitis: ethnopharmacological rationale, pharmacology, clinical evidence, and safety}},
author = {Chunyu Ma and Cuiping Yang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1972684},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1972684/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Five-flavor Sophora flavescens enteric-coated capsules for ulcerative colitis: ethnopharmacological rationale, pharmacology, clinical evidence, and safety
AU - Chunyu Ma
AU - Cuiping Yang
PY - 2026
DA - 2026/10/22
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1972684
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1972684/full
AB - Five-flavor Sophora flavescens enteric-coated capsules (FSEC), also reported as Wuwei Kushen or composite Sophora colon-soluble capsules, are used in China for ulcerative colitis (UC) associated with intestinal damp-heat, bloody diarrhea, and mucosal injury. This critical narrative Review evaluates the traditional rationale, product identity, material basis, pharmacological evidence, clinical findings, and safety of FSEC. PubMed, Web of Science, ScienceDirect, CNKI, Wanfang, and reference lists were searched through May 2026 and selectively updated through 18 August 2026. The Four Pillars of Best Practice in Ethnopharmacology and the ConPhyMP guidelines informed appraisal of identity, characterization, dose, and evidence attribution. The defined five-material product contains S. flavescens , Sanguisorba officinalis , Indigo naturalis, Bletilla striata , and Glycyrrhiza uralensis . Complete-formulation experiments support effects on microbial short-chain-fatty-acid signaling, GPR43, NLRP3/STAT3, AGE-RAGE/NF-κB, epithelial barrier integrity, and ferroptosis-related changes. Constituent studies broaden biological plausibility but cannot establish the efficacy or safety of the complete product. Older randomized trials and meta-analyses suggest short-term benefit, whereas recent single-center cohorts provide provisional adjunctive evidence because of nonrandomized designs and incomplete batch reporting. FSEC is therefore a plausible colon-targeted ethnopharmacological intervention, but confirmatory studies require chemically defined batches, verified release and exposure, internationally accepted UC endpoints, prospective multicenter designs, and active monitoring for hepatic, cardiopulmonary, electrolyte, and interaction risks.
SN - 1663-9812
ER -